David E I Pyott

Director David E I Pyott sells 3,830 shares at avg $299.18 under pre-arranged 10b5-1 plan; retains 1,582 shares post-transaction.

Director David E I Pyott executed 5 separate sales totaling 3,830 shares for $1,145,852.75 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-12, reducing his non-derivative holdings by 70.8% from 5,412 shares to 1,582 shares. The sales were executed at prices ranging from $297.71 to $302.65, yielding a blended average price of $299.18, against a current market price of $292.58. Because this transaction is governed by a scheduled 10b5-1 plan rather than discretionary choice, the filing reflects automatic execution rather than a market-timing decision by the insider. The company's fundamentals show strong growth (annual revenue growth of 65.2%, net income of $251.1M on $1.2B quarterly revenue) and a market cap of $38.8B, though the stock is currently -41.0% from its 52-week high of $495.55. His prior sales at ALNY show mixed timing outcomes (the most recent sale on 2025-03-24 saw a 30-day decline of -19.1%), though this specific filing represents scheduled divestiture rather than discretionary positioning.

Director DAVID E I PYOTT sold 7,440 shares of ALNY at $299.00 (2025-03-24), reducing stake by -98.2% to 136 shares ($2,224,560 total).

DAVID E I PYOTT, a director at unprofitable ALNYLAM PHARMACEUTICALS (net income: $-111,570,000), divested 7,440 shares at $299.00, retaining just 136 shares—a near-complete exit from a $36.4B market-cap position. The sale occurred near the 52-week high ($300.55), with the stock having risen 15.5% over 90 days and 12.1% over 30 days prior. His historical track record at this ticker shows three prior sells in June 2024, all followed by subsequent 90-day gains (ranging +23.4% to +24.5%), indicating a 0% success rate in timing sell exits at ALNY. The near-total liquidation of a long-held directorship stake, combined with the company's persistent unprofitability ($500.9M revenue against $-111.6M net income) and prior ill-timed exit patterns, warrants close attention to the fundamental investment thesis.

ALNY Director David Pyott sells 32,450 shares (99.6% of holdings) for $7,161,360 across 3 transactions at $220–$222 on 2024-06-24

David Pyott, a director at Alnylam Pharmaceuticals, executed 3 separate sales on 2024-06-24 totaling 32,450 shares for $7,161,360, reducing his holdings from 32,586 shares to 136 shares—a near-complete exit (-99.6%). The sales were executed at prices ranging from $220.00 to $222.00 (blended average $220.69), occurring while the stock currently trades at $245.17, well above the transaction prices. Alnylam remains unprofitable (latest full fiscal year net income was negative) despite strong revenue growth (+76.2% annually) and a substantial market cap of $31,011,989,212.26. The magnitude of the position reduction—disposing of virtually the entire holdings—stands out as a material event in terms of insider exposure and warrants examination of related Form 5 filings and director compensation structure to determine whether this reflects restricted equity vesting or a discretionary strategic decision.